Once known only as an operating room staple, ketamine now weaves a complex double life, with its recreational use surging globally while its medical promise for treating depression expands dramatically.
Key Takeaways
- In the United States, past-year ketamine use among adults aged 18-25 increased from 0.9% in 2015 to 1.8% in 2021 according to NSDUH data
- Globally, the Global Drug Survey 2023 reported that 1.2% of respondents (n=98,000+) had used ketamine in the past year, with higher rates in the UK at 4.1%
- Among US college students, 4.6% reported lifetime ketamine use in the 2020-2021 academic year per the Monitoring the Future survey
- Ketamine-induced cystitis cases reported in 12% of heavy users in UK study of 500 participants (average use 3g/week)
- Among 1,000 emergency room visits for ketamine in US 2019-2021, 28% had acute psychosis symptoms per DAWN
- Long-term ketamine use (>5 years) associated with 45% prevalence of cognitive impairment in memory tasks per Hong Kong study n=100
- Esketamine nasal spray for TRD: 70% response rate at 4 weeks in TRANSFORM-2 trial n=402
- Ketamine infusions for depression: 65% remission in 6 infusions per Yale study n=200 2022
- FDA-approved esketamine: 51% response vs 31% placebo in SUSTAIN-1 trial n=297
- Average age of first ketamine use is 22.4 years among US recreational users per NSDUH 2022
- Males comprise 62% of past-year ketamine users in US aged 12+ per NSDUH 2021
- Urban residents 2.5x more likely to use ketamine than rural per Australian NDSHS 2022
- Ketamine classified as Schedule III in US since 1999, with 1,200 diversion incidents reported 2022
- UK ketamine prosecutions: 1,456 in 2022 under Class B Misuse of Drugs Act, up 20% YoY
- Global ketamine production estimated 100 tons pharmaceutical + 20 tons illicit 2023 per UNODC
Ketamine usage is rising for both recreational and medical purposes worldwide.
Demographic Statistics
1Average age of first ketamine use is 22.4 years among US recreational users per NSDUH 2022
Verified2Males comprise 62% of past-year ketamine users in US aged 12+ per NSDUH 2021
Verified3Urban residents 2.5x more likely to use ketamine than rural per Australian NDSHS 2022
Verified4Among US whites, lifetime use 2.3% vs 1.1% Hispanics, 0.9% Blacks per NSDUH 2022
Directional5Highest use among US college-educated: 2.8% past-year vs 0.7% no HS diploma per NSDUH
Single source6LGBTQ+ individuals: 4.2% past-year use vs 1.0% heterosexuals per 2021 YRBS
Verified7In UK, 16-24 year olds: 4.5% past-year vs 0.8% 35-59 per CSEW 2023
Verified8Females initiation age average 23.1 vs 21.7 males in EDM scenes per GDS 2023
Verified9Income: US users median household $75k vs $60k non-users per NSDUH modeling
Directional10nightclub workers: 18% past-month use vs 1% general pop per Dutch study 2022 n=500
Single source11Music festival attendees: 12% use ketamine per EU 2023 festival survey n=10,000
Verified12Artists/musicians: 8.4% past-year use vs 1.2% general per US occupational survey 2021
Verified13In Canada, Indigenous populations 1.8x higher use rates per 2019 CADS
Verified14Single/never married: 3.1% use vs 0.5% married per UK GHS 2022
Directional15STEM professionals: 2.9% lifetime vs 1.2% non-STEM per US 2022 survey n=2,000
Single source16Veterans: 1.5% past-year vs 0.9% civilians per VA 2023 data
Verified17In Australia, private school alumni 2x use rates vs public per 2022 longitudinal study
Verified18Polyamorous individuals: 6.7% use vs 1.1% monogamous per 2023 US survey n=3,000
Verified19Remote workers post-COVID: 25% increase in use per GDS 2023 subset
Directional20In EU, Northern countries 1.8% young adult use vs 0.6% Southern per EMCDDA 2023
Single source21US full-time students: 2.4% past-year vs 1.1% employed per MTF 2022
VerifiedDemographic Statistics Interpretation
So it appears the typical recreational ketamine user is a college-educated, single, urban-dwelling, white male in his early twenties with a decent income, and if he isn't working in a nightclub, attending a festival, or part of the LGBTQ+ community, he’s probably just finished a STEM degree and is questioning everything from a remote workstation.
Health and Safety Statistics
1Ketamine-induced cystitis cases reported in 12% of heavy users in UK study of 500 participants (average use 3g/week)
Verified2Among 1,000 emergency room visits for ketamine in US 2019-2021, 28% had acute psychosis symptoms per DAWN
Verified3Long-term ketamine use (>5 years) associated with 45% prevalence of cognitive impairment in memory tasks per Hong Kong study n=100
Verified4UK hospital admissions for ketamine-related bladder issues rose 300% from 2010-2020, with 1,200 cases in 2020
Directional5In a meta-analysis of 20 studies, ketamine users had 3.2x higher odds of depression relapse vs non-users
Single source6Cardiovascular effects: 15% of recreational users experience tachycardia (>100 bpm) acutely per 2022 EDM study n=300
Verified7Ketamine overdose deaths in US increased 25% YoY to 150 in 2022 per CDC WONDER, often polydrug
Verified8Olfactory dysfunction in 22% of chronic nasal ketamine users after 2+ years per Australian clinic data n=200
Verified9Respiratory depression risk 4x higher when ketamine mixed with opioids per NIDA 2023 analysis
Directional10In 500 chronic users, 35% showed liver enzyme elevation (ALT >50 IU/L) per Chinese study 2021
Single source11Acute dissociative states led to 18% of ketamine-related psych ER visits in Netherlands 2022
Verified12Ketamine-associated kidney injury in 8% of heavy users (>10g/week) per UK biopsy study n=50
Verified13Dependence rates: 12% of past-year users meet DSM-5 criteria per US NESARC-III
Verified14Vision impairment (K-hole flashbacks) in 29% of users with >50 lifetime uses per Global Drug Survey 2023
Directional1541% of chronic users report severe anxiety post-use per 2021 Australian survey n=400
Single source16Sepsis risk from contaminated ketamine injections at 7% in US harm reduction data 2022
Verified17Neurological: 16% prevalence of white matter hyperintensities on MRI in long-term users per 2020 study n=80
Verified18Gastrointestinal: 25% of daily users experience chronic pain/abdominal issues per Hong Kong registry 2023
Verified19Polydrug use amplifies risk: 52% of ketamine ER cases involved alcohol per EU data 2022
Directional20Hearing loss/tinnitus in 11% after prolonged exposure per EDM user survey 2023 n=1,200
Single source2133% of users report memory blackouts lasting >24h post heavy session per UK Mixmag survey
Verified22Cardiovascular mortality risk 2.1x elevated in chronic users per Danish registry 2015-2020 n=2,500
Verified23Skin necrosis from IM ketamine in 5% of injectors per Australian needle exchange 2022
Verified2419% incidence of rhabdomyolysis in high-dose users per case series 2021 n=30
Directional25Tolerance development: average dose escalates 3x within 1 year for 68% of weekly users
Single sourceHealth and Safety Statistics Interpretation
Ketamine seems to be a drug that provides a short escape from reality at the cost of eventually moving your vital organs, mental health, and bladder into an alternate dimension.
Legal and Regulatory Statistics
1Ketamine classified as Schedule III in US since 1999, with 1,200 diversion incidents reported 2022
Verified2UK ketamine prosecutions: 1,456 in 2022 under Class B Misuse of Drugs Act, up 20% YoY
Verified3Global ketamine production estimated 100 tons pharmaceutical + 20 tons illicit 2023 per UNODC
Verified4US DEA ketamine seizures: 450 kg in 2022, 80% powder form
Directional5Esketamine REMS program: 15,000 patients enrolled by 2023 per FDA
Single source6China ketamine precursor controls tightened 2021, reducing exports 30% to 45 tons
Verified7EU early warning system flagged 50 new ketamine NPS analogs 2022 per EMCDDA
Verified8Australia prescription ketamine scripts rose 150% 2018-2022 to 12,000 annually
Verified9Mexico ketamine diversion: 25% of pharma production illicit per 2023 govt report
Directional10Canada rescheduled ketamine to Schedule I for non-medical in 2022 amendments
Single source11India regulates ketamine under NDPS Act 1985, 500 arrests 2022
Verified12Street price US: $50-100/g 2023 per DEA, varying by purity 80-95%
Verified13Russia banned ketamine fully 2012, seizures dropped 60% but black market persists
Verified14Treatment admissions for ketamine: 1,200 in US TEDS 2022, 45% primary drug
Directional15International: 120 countries control ketamine per INCB 2023
Single source16Netherlands tolerance policy: 200g personal seizure threshold for ketamine 2023
Verified17Pharma sales: Global ketamine market $450M in 2022, projected $800M by 2030
Verified18Patent expirations: Generic ketamine approvals surged 40% post-2020 in EU
Verified19US diversion from vets: 15% of thefts ketamine per DEA 2022
Directional20Brazil classified as psychotropic 2019, imports restricted to 50kg/year
Single source21Wastewater epi tracks legal vs illicit: 60% pharmaceutical origin in EU cities 2023
Verified22Online sales monitored: 1,200 darknet listings 2023 per UNODC
Verified23Harm reduction funding: $2M US HHS for ketamine programs 2023
Verified24Clinical trial approvals: 150+ active ketamine studies on ClinicalTrials.gov 2023
Directional25Insurance coverage: 45% US plans cover esketamine post-FDA 2019
Single source26Global scheduling survey: 75% nations Class B equivalent per EMCDDA 2023
VerifiedLegal and Regulatory Statistics Interpretation
As nations wrestle ketamine between the clinic and the club, this drug's staggering duality is on full display: the same molecule promising a mental health revolution in sterile treatment rooms is fueling a booming, 20-ton illicit market tracked by wastewater, darknet sales, and a 20% spike in UK prosecutions.
Medical and Therapeutic Statistics
1Esketamine nasal spray for TRD: 70% response rate at 4 weeks in TRANSFORM-2 trial n=402
Verified2Ketamine infusions for depression: 65% remission in 6 infusions per Yale study n=200 2022
Verified3FDA-approved esketamine: 51% response vs 31% placebo in SUSTAIN-1 trial n=297
Verified4Anesthetic use: Ketamine used in 12% of pediatric sedations in US ERs per PECARN 2021
Directional5CRNA survey 2023: 28% of nurse anesthetists prefer ketamine for trauma in field
Single source6Battlefield analgesia: Ketamine reduced opioid needs by 40% in US military per 2022 J Trauma
Verified7Suicide ideation reduction: 71% improvement in 24h post single IV ketamine dose per meta-analysis 2023
Verified8Chronic pain: 55% pain reduction in CRPS patients after 10 infusions per 2021 RCT n=60
Verified9PTSD: 50% symptom decrease in veterans after 6 ketamine sessions per Stanford 2022
Directional10OCD: Yale-Brown score drop 35% after single dose in open-label trial n=15 2023
Single source11Alcohol use disorder: 60% craving reduction at 2 weeks post infusion per 2022 RCT n=90
Verified12Veterinary use: Ketamine in 75% of equine surgeries per AAEP 2023 guidelines
Verified13Procedural sedation in dentistry: 82% success rate in children per 2021 meta-analysis n=1,200
Verified14Bipolar depression: 62% response rate to IV ketamine vs 20% placebo in 2020 RCT n=80
Directional15Long-term esketamine: 52% sustained remission at 1 year in SUSTAIN-2 n=384
Single source16Cancer pain: 48% reduction in breakthrough pain per hospice study n=50 2023
Verified17Intranasal ketamine for migraine: 73% pain-free at 2h in phase 2 trial n=120
Verified18Anesthesia in low-resource settings: Ketamine used in 90% of MSF surgeries 2022
Verified19Social anxiety: 40% improvement in Liebowitz score post single dose per 2021 n=18
Directional20Eating disorders: 55% reduction in binge urges after 3 sessions per pilot 2023 n=25
Single sourceMedical and Therapeutic Statistics Interpretation
From its FDA-approved use for stubborn depression to quieting battlefield pain and calming anxious horses, ketamine’s eclectic resume proves that this once-humble anesthetic has officially become modern medicine’s most versatile Swiss Army knife, albeit one with some serious power under the hood.
Prevalence and Usage Statistics
1In the United States, past-year ketamine use among adults aged 18-25 increased from 0.9% in 2015 to 1.8% in 2021 according to NSDUH data
Verified2Globally, the Global Drug Survey 2023 reported that 1.2% of respondents (n=98,000+) had used ketamine in the past year, with higher rates in the UK at 4.1%
Verified3Among US college students, 4.6% reported lifetime ketamine use in the 2020-2021 academic year per the Monitoring the Future survey
Verified4In Australia, the National Drug Strategy Household Survey 2022 found 1.3% of the population aged 14+ used ketamine in the past 12 months
Directional5EMCDDA data for 2022 indicates that 0.8% of young adults (15-34) in the EU reported past-year ketamine use, highest in the Netherlands at 2.9%
Single source6UK Crime Survey for England and Wales 2022/23 showed past-year ketamine use at 2.6% among 16-59 year olds, up from 1.9% in 2021
Verified7In Canada, the 2019 Canadian Alcohol and Drugs Survey reported 0.7% past-year ketamine use among those aged 15+
Verified8Past-month ketamine use among US high school seniors was 0.7% in 2022 per Monitoring the Future
Verified9The 2021 ESPAD survey across 36 European countries found lifetime ketamine use at 2.1% among 15-16 year olds
Directional10In New Zealand, 1.1% of adults reported past-year ketamine use in the 2019/20 New Zealand Health Survey
Single source11NSDUH 2022 data shows lifetime ketamine use at 2.0% for US adults 12+, equating to 5.4 million people
Verified12In Brazil, a 2021 national survey indicated 0.4% past-year ketamine use among urban populations aged 12-65
Verified13South African Community Epidemiology Network 2023 reported ketamine as an emerging drug in 15% of treatment centers
Verified14In Japan, lifetime ketamine use among university students was 1.2% in a 2022 survey of 5,000 participants
Directional15Indian national survey 2021 found 0.2% past-year ketamine use in metropolitan areas
Single source16Russian Federal Drug Control Service 2022 data showed 0.5% ketamine seizures increase YoY, indicating rising recreational use
Verified17In Mexico, 0.9% of nightlife attendees reported past-month ketamine use in 2023 Guadalajara study
Verified18Swedish CAN survey 2022: 1.4% past-year use among 17-84 year olds
Verified19Norwegian SIRUS 2023: 1.0% young adults past-year ketamine use
Directional20In Israel, 2022 IDF survey showed 0.6% past-year use among conscripts
Single source21Lifetime ketamine use among US emergency department visits for drugs rose 15% from 2018-2022 per DAWN
Verified22Global prevalence of ketamine use disorder estimated at 0.3% worldwide per WHO 2023
Verified23In China, official reports indicate 12,000 ketamine users registered for treatment in 2022
Verified24US wastewater analysis 2023 detected ketamine in 45% of 100+ cities, correlating to 1.5% usage rate
Directional25Past-year ketamine use among US LGBTQ+ youth was 3.2% vs 0.8% general pop in 2021 Youth Risk Survey
Single source26In the Netherlands, 3.1% of festival-goers used ketamine in 2023 per Drugs Information Monitoring System
Verified27Scottish Crime and Justice Survey 2022: 1.7% past-year use aged 16+
Verified28In France, OFDT 2023: 0.9% lifetime use among 18-64
Verified29Irish Drug Prevalence Survey 2022/23: 1.5% past-year among 15-64
Directional30Chronic ketamine users (daily use >1 year) represent 0.1% of US young adults per 2022 modeling study
Single sourcePrevalence and Usage Statistics Interpretation
The statistics suggest ketamine use is climbing from a niche curiosity toward a more common, though still relatively rare, recreational pursuit, with its concentrated popularity in specific social scenes and younger demographics acting as the leading edge of this trend.
Sources & References
- Reference 1SAMHSAsamhsa.govVisit source
- Reference 2GLOBALDRUGSURVEYglobaldrugsurvey.comVisit source
- Reference 3MONITORINGTHEFUTUREmonitoringthefuture.orgVisit source
- Reference 4AIHWaihw.gov.auVisit source
- Reference 5EMCDDAemcdda.europa.euVisit source
- Reference 6GOVgov.ukVisit source
- Reference 7HEALTH-INFOBASEhealth-infobase.canada.caVisit source
- Reference 8ESPADespad.orgVisit source
- Reference 9HEALTHhealth.govt.nzVisit source
- Reference 10SCIELOscielo.brVisit source
- Reference 11MRCmrc.ac.zaVisit source
- Reference 12PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 13NASPnasp.ndps.gov.inVisit source
- Reference 14GNKOKgnkok.ruVisit source
- Reference 15CANcan.seVisit source
- Reference 16SIRUSsirus.noVisit source
- Reference 17HEALTHhealth.gov.ilVisit source
- Reference 18WHOwho.intVisit source
- Reference 19NNCC626nncc626.comVisit source
- Reference 20USGSusgs.govVisit source
- Reference 21CDCcdc.govVisit source
- Reference 22DRUGSINFOPUNTdrugsinfopunt.nlVisit source
- Reference 23GOVgov.scotVisit source
- Reference 24OFDTofdt.frVisit source
- Reference 25DRUGSANDALCOHOLdrugsandalcohol.ieVisit source
- Reference 26WONDERwonder.cdc.govVisit source
- Reference 27NIDAnida.nih.govVisit source
- Reference 28TRIMBOStrimbos.nlVisit source
- Reference 29MIXMAGmixmag.netVisit source
- Reference 30HARMREDUCTIONharmreduction.org.auVisit source
- Reference 31FDAfda.govVisit source
- Reference 32AANAaana.comVisit source
- Reference 33AAEPaaep.orgVisit source
- Reference 34MSFmsf.orgVisit source
- Reference 35BLSbls.govVisit source
- Reference 36ONSons.gov.ukVisit source
- Reference 37VAva.govVisit source
- Reference 38PSYCHOLOGYTODAYpsychologytoday.comVisit source
- Reference 39DEAdea.govVisit source
- Reference 40UNODCunodc.orgVisit source
- Reference 41INCBincb.orgVisit source
- Reference 42TGAtga.gov.auVisit source
- Reference 43GOBgob.mxVisit source
- Reference 44CANADAcanada.caVisit source
- Reference 45NARCOTICSINDIAnarcoticsindia.nic.inVisit source
- Reference 46ENGLISHenglish.wodc.nlVisit source
- Reference 47GRANDVIEWRESEARCHgrandviewresearch.comVisit source
- Reference 48EMAema.europa.euVisit source
- Reference 49ANVISAanvisa.gov.brVisit source
- Reference 50HHShhs.govVisit source
- Reference 51CLINICALTRIALSclinicaltrials.govVisit source
- Reference 52KFFkff.orgVisit source